Compare TGT & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGT | TAK |
|---|---|---|
| Founded | 1902 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 56.5B |
| IPO Year | 1994 | N/A |
| Metric | TGT | TAK |
|---|---|---|
| Price | $120.08 | $18.08 |
| Analyst Decision | Buy | |
| Analyst Count | 28 | 0 |
| Target Price | ★ $117.42 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 2.4M |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.77% | 2.95% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.84 | N/A |
| Revenue | ★ $72,618,000,000.00 | N/A |
| Revenue This Year | $2.80 | $0.04 |
| Revenue Next Year | $3.02 | $0.92 |
| P/E Ratio | ★ $20.61 | $41.25 |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $83.44 | $12.99 |
| 52 Week High | $126.00 | $18.82 |
| Indicator | TGT | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 53.16 |
| Support Level | $93.23 | $14.78 |
| Resistance Level | N/A | $18.82 |
| Average True Range (ATR) | 3.57 | 0.25 |
| MACD | 0.13 | -0.17 |
| Stochastic Oscillator | 58.93 | 42.72 |
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $106 billion in fiscal 2024 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2024 revenue), beauty and household essentials (30%), food and beverage (23%), hardlines (15%), as well as home furnishings (16%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.